← Back to Screener
Candel Therapeutics, Inc. Common Stock (CADL)
Price$7.22
Favorite Metrics
Price vs S&P 500 (26W)-5.84%
Price vs S&P 500 (4W)18.68%
Market Capitalization$466.58M
All Metrics
Book Value / Share (Quarterly)$0.95
P/TBV (Annual)0.59x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.71
Price vs S&P 500 (YTD)8.61%
Net Profit Margin (TTM)-15156.45%
EPS (TTM)$-0.70
10-Day Avg Trading Volume1.34M
EPS Excl Extra (TTM)$-0.70
EPS (Annual)$-1.74
ROI (Annual)-70.00%
Cash / Share (Quarterly)$2.18
ROA (Last FY)-51.63%
EBITD / Share (TTM)$-0.72
ROE (5Y Avg)-109.18%
Operating Margin (TTM)-28000.81%
Cash Flow / Share (Annual)$-0.71
P/B Ratio8.99x
P/B Ratio (Quarterly)5.97x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)3177.27x
Net Interest Coverage (TTM)-53.96x
ROA (TTM)-36.31%
EPS Incl Extra (Annual)$-1.74
Current Ratio (Annual)13.49x
Quick Ratio (Quarterly)13.31x
3-Month Avg Trading Volume1.11M
52-Week Price Return40.62%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.80
P/S Ratio (Annual)3732.66x
Asset Turnover (Annual)0.00x
52-Week High$7.25
EPS Excl Extra (Annual)$-1.74
CapEx CAGR (5Y)-16.84%
26-Week Price Return2.91%
Quick Ratio (Annual)13.31x
13-Week Price Return2.58%
Total Debt / Equity (Annual)0.91x
Current Ratio (Quarterly)13.49x
Enterprise Value$393.982
Asset Turnover (TTM)0.00x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-15035.20%
Cash / Share (Annual)$2.18
3-Month Return Std Dev79.20%
Net Income / Employee (TTM)$-1
ROE (Last FY)-83.19%
Net Interest Coverage (Annual)-92.94x
EPS Basic Excl Extra (Annual)$-1.74
Total Debt / Equity (Quarterly)0.91x
EPS Incl Extra (TTM)$-0.70
ROI (TTM)-41.62%
P/S Ratio (TTM)3762.77x
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.65
Price vs S&P 500 (52W)5.52%
Year-to-Date Return12.74%
5-Day Price Return30.80%
EPS Normalized (Annual)$-1.74
ROA (5Y Avg)-50.92%
Net Profit Margin (Annual)-15035.20%
Month-to-Date Return30.00%
Cash Flow / Share (TTM)$-1.07
EBITD / Share (Annual)$-1.68
Operating Margin (Annual)-27777.60%
LT Debt / Equity (Annual)0.91x
ROI (5Y Avg)-66.33%
LT Debt / Equity (Quarterly)0.91x
EPS Basic Excl Extra (TTM)$-0.70
P/TBV (Quarterly)1.23x
P/B Ratio (Annual)5.97x
Pretax Margin (TTM)-15156.45%
Book Value / Share (Annual)$0.95
Price vs S&P 500 (13W)-0.29%
Beta-0.55x
Revenue / Share (TTM)$0.00
ROE (TTM)-51.44%
52-Week Low$4.34
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CADLCandel Therapeutics, Inc. Common Stock | 3762.77x | — | — | — | $7.22 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 11.09x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Candel Therapeutics is a clinical-stage biopharmaceutical company developing viral immunotherapies designed to activate immune responses against cancer. The company operates two proprietary viral platforms based on genetically modified adenovirus and herpes simplex virus (HSV) constructs, positioning it in the emerging viral oncology sector.